基础胰岛素不足与失败——使用恰当的术语
Basal Insulin Inadequacy versus Failure - Using Appropriate Terminology.
作者信息
Kalra Sanjay, Gupta Yashdeep
机构信息
Department of Endocrinology, Bharti Hospital, Karnal, India.
Department of Endocrinology, All India Institute of Medical Sciences, New Delhi, India.
出版信息
Eur Endocrinol. 2015 Aug;11(2):79-80. doi: 10.17925/EE.2015.11.02.79. Epub 2015 Aug 19.
Abstract
This editorial focuses on appropriate terminology related to basal insulin therapy. The authors analyse current usage of 'basal insulin failure', and propose 'basal insulin inadequacy' as a better descriptor for persons not responding to basal insulin alone. The pharmacokinetic and pharmacodynamic differences between various basal insulin preparations are highlighted. Based upon these, a drug-specific definition for insulin inadequacy is suggested, instead of a generic class-based labelling.
摘要
本社论聚焦于与基础胰岛素治疗相关的恰当术语。作者分析了“基础胰岛素失效”一词的当前用法，并提出“基础胰岛素不足”作为对仅使用基础胰岛素无反应者的更合适描述。文中强调了各种基础胰岛素制剂之间的药代动力学和药效学差异。基于这些差异，建议针对胰岛素不足给出特定药物的定义，而非基于通用类别的标签。
相似文献
1
Basal Insulin Inadequacy versus Failure - Using Appropriate Terminology.基础胰岛素不足与失败——使用恰当的术语
Eur Endocrinol. 2015 Aug;11(2):79-80. doi: 10.17925/EE.2015.11.02.79. Epub 2015 Aug 19.
2
Clinical relevance of pharmacokinetic and pharmacodynamic profiles of insulin degludec (100, 200 U/mL) and insulin glargine (100, 300 U/mL) - a review of evidence and clinical interpretation.胰岛素地特胰岛素（100、200 U/mL）和甘精胰岛素（100、300 U/mL）的药代动力学和药效学特征的临床相关性-证据回顾与临床解读。
Diabetes Metab. 2019 Sep;45(4):330-340. doi: 10.1016/j.diabet.2018.11.004. Epub 2018 Nov 26.
3
The past, present, and future of basal insulins.基础胰岛素的过去、现在和未来。
Diabetes Metab Res Rev. 2016 Sep;32(6):478-96. doi: 10.1002/dmrr.2763. Epub 2015 Nov 25.
4
Cardiovascular effects of basal insulins.基础胰岛素的心血管效应。
Drug Healthc Patient Saf. 2015 Jul 10;7:113-20. doi: 10.2147/DHPS.S43300. eCollection 2015.
5
The role of new basal insulin analogues in the initiation and optimisation of insulin therapy in type 2 diabetes.新型基础胰岛素类似物在2型糖尿病胰岛素治疗起始及优化中的作用
Acta Diabetol. 2008 Dec;45(4):253-68. doi: 10.1007/s00592-008-0052-9. Epub 2008 Sep 3.
6
Basal insulin analogues in the management of diabetes mellitus: What progress have we made?基础胰岛素类似物在糖尿病治疗中的应用：我们取得了哪些进展？
Diabetes Metab Res Rev. 2014 Feb;30(2):104-19. doi: 10.1002/dmrr.2469.
7
Insulin degludec: a novel ultra-long-acting basal insulin for use in Type 1 and 2 diabetes.德谷胰岛素：一种用于1型和2型糖尿病的新型超长效基础胰岛素。
Expert Rev Endocrinol Metab. 2012 Jan;7(1):9-14. doi: 10.1586/eem.11.86.
8
Switching from twice-daily glargine or detemir to once-daily degludec improves glucose control in type 1 diabetes. An observational study.从每日两次甘精胰岛素或地特胰岛素转换为每日一次德谷胰岛素可改善1型糖尿病患者的血糖控制。一项观察性研究。
Nutr Metab Cardiovasc Dis. 2016 Dec;26(12):1112-1119. doi: 10.1016/j.numecd.2016.08.002. Epub 2016 Aug 6.
9
Comparative Benefits and Harms of Basal Insulin Analogues for Type 2 Diabetes: A Systematic Review and Network Meta-analysis.比较 2 型糖尿病基础胰岛素类似物的获益与危害：系统评价和网络荟萃分析。
Ann Intern Med. 2018 Aug 7;169(3):165-174. doi: 10.7326/M18-0443. Epub 2018 Jul 10.
10
A comparison of insulin detemir and neutral protamine Hagedorn (isophane) insulin in the treatment of diabetes: a systematic review.胰岛素地特胰岛素与中性鱼精蛋白锌胰岛素（精蛋白锌胰岛素）治疗糖尿病的比较：系统评价。
Diabetes Obes Metab. 2013 Nov;15(11):978-86. doi: 10.1111/dom.12106. Epub 2013 May 1.
引用本文的文献
1
Clinical Characteristics of Patients Responding to Once-Daily Basal Insulin Therapy in Korean Subjects with Type 2 Diabetes.韩国2型糖尿病患者每日一次基础胰岛素治疗的应答者临床特征
Diabetes Ther. 2015 Dec;6(4):547-558. doi: 10.1007/s13300-015-0140-0. Epub 2015 Oct 29.
本文引用的文献
1
Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.2015年2型糖尿病高血糖管理：以患者为中心的方法：美国糖尿病协会和欧洲糖尿病研究协会立场声明更新版
Diabetes Care. 2015 Jan;38(1):140-9. doi: 10.2337/dc14-2441.
2
Switching from insulin glargine to insulin degludec reduced HbA1c, daily insulin doses and anti-insulin antibody in anti-insulin antibody-positive subjects with type 1 diabetes.在1型糖尿病抗胰岛素抗体阳性的受试者中，从甘精胰岛素转换为德谷胰岛素可降低糖化血红蛋白、每日胰岛素剂量和抗胰岛素抗体。
Diabetes Metab. 2014 Dec;40(6):481-2. doi: 10.1016/j.diabet.2014.09.003.
3
Cost-effectiveness of insulin degludec compared with insulin glargine in a basal-bolus regimen in patients with type 1 diabetes mellitus in the UK.在英国1型糖尿病患者的基础-餐时胰岛素治疗方案中，德谷胰岛素与甘精胰岛素的成本效益比较。
J Med Econ. 2015 Jan;18(1):56-68. doi: 10.3111/13696998.2014.971160. Epub 2014 Oct 21.
4
Is insulin degludec a more effective treatment for patients using high doses of insulin glargine but not attaining euglycemia? Some case reports from India.对于使用大剂量甘精胰岛素但仍未达到血糖正常的患者，德谷胰岛素是否是一种更有效的治疗方法？来自印度的一些病例报告。
Diabetes Metab Syndr Obes. 2014 Jun 23;7:225-8. doi: 10.2147/DMSO.S63878. eCollection 2014.
5
Newer basal insulin analogues: degludec, detemir, glargine.新型基础胰岛素类似物：德谷胰岛素、地特胰岛素、甘精胰岛素。
J Pak Med Assoc. 2013 Nov;63(11):1442-4.
6
Cost-effectiveness of insulin degludec compared with insulin glargine for patients with type 2 diabetes treated with basal insulin - from the UK health care cost perspective.从英国医疗保健成本角度看，德谷胰岛素对比甘精胰岛素用于治疗基础胰岛素的 2 型糖尿病患者的成本效益。
Diabetes Obes Metab. 2014 Apr;16(4):366-75. doi: 10.1111/dom.12250. Epub 2014 Jan 16.
7
Insulin degludec: a significant advancement in ultralong-acting Basal insulin.德谷胰岛素：超长效基础胰岛素的重大进展。
Diabetes Ther. 2013 Dec;4(2):167-73. doi: 10.1007/s13300-013-0047-6. Epub 2013 Nov 20.
8
Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials.与甘精胰岛素相比，德谷胰岛素治疗 2 型和 1 型糖尿病的低血糖风险：一项 3 期临床试验的预先计划的荟萃分析。
Diabetes Obes Metab. 2013 Feb;15(2):175-84. doi: 10.1111/dom.12032. Epub 2012 Dec 3.
9
Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long).在 2 型糖尿病的胰岛素初治患者中，德谷胰岛素对比甘精胰岛素：一项为期 1 年、随机、以目标为导向的试验（BEGIN Once Long）。
Diabetes Care. 2012 Dec;35(12):2464-71. doi: 10.2337/dc12-1205. Epub 2012 Oct 5.
10
Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes.在 1 型糖尿病患者中，稳态条件下德谷胰岛素的药效变异性比甘精胰岛素低四倍。
Diabetes Obes Metab. 2012 Sep;14(9):859-64. doi: 10.1111/j.1463-1326.2012.01627.x. Epub 2012 Jun 7.
Zotero 插件